共 50 条
- [1] PREDICTORS OF OVERALL SURVIVAL (OS) AND TIME TO NEXT TREATMENT (TTNT) IN REAL-WORLD METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (mPDAC) PATIENTS WHO RECEIVED FIRST-LINE (1L) FOLFIRINOX (FFX) OR GEMCITABINE plus NAB-PACLITAXEL (GnP)VALUE IN HEALTH, 2024, 27 (06) : S22 - S22Dennen, S.Silver, M.Cockrum, P.Kim, G. P.
- [2] Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Paluri, Ravi KumarSilver, MichelleCockrum, PaulDennen, Syvart
- [3] Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine plus nab-paclitaxel (GnP).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 693 - 693Dennen, SyvartMasek, MartyCockrum, PaulPaluri, Ravi Kumar
- [4] Real-world use of supportive medications to prevent and manage key adverse events during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine plus nab-paclitaxel (GnP)JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 695 - 695Dennen, SyvartMasek, MartyCockrum, PaulPaluri, Ravi Kumar
- [5] Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kim, George P.Silver, MichelleSanders, ChadCockrum, PaulMacEwan, Joanna P.Duncan, Dan
- [6] Real-world dose intensity (DI) and time to adverse events (AEs) in a commercial database during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine plus nab-paclitaxel (GnP).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 692 - 692Dennen, SyvartMasek, MartyCockrum, PaulPaluri, Ravi Kumar
- [7] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Cartwright, Thomas H.Parisi, MonikaEspirito, Janet L.Wilson, ThomasPelletier, CoreyPatel, ManishBabiker, Hani M.
- [8] Costs of generic vs. branded nab-paclitaxel (nP) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with gemcitabine plus nab-paclitaxel (GnP) in a real-world commercial database.JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)Dennen, SyvartMasek, MartyNaga, Sai Sriteja BoppudiCockrum, PaulPaluri, Ravi Kumar
- [9] Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOXJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Dieguez, GabrielaTomicki, SamanthaCockrum, PaulHirsch, JaredBhatt, PrachiKim, George P.
- [10] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first lineJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)MacEwan, Joanna P.Silver, MichelleCockrum, PaulSanders, ChadKim, George P.